Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02766335 · ClinicalTrials.gov registry record · Phase 2
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
A Phase 2 study of Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 20
- Study locations
NCT02766335 is a Phase 2 study of Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7 that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 116 participants, roughly in line with the 123-participant average among 3 other Recurrent Squamous Cell Lung Carcinoma trials with a reported enrollment target. The trial reports 20 study locations across 5 states.
The verdict
NCT02766335, a Phase 2 study of Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well durvalumab works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a "non-match" sub-study that includes all screened patients not eligible for a biomarker-driven sub-study. Monoclonal antibodies, such as durvalumab, may be able to shrink tumors. Durvalumab may be effective in treating patients with squamous cell lung cancer.
Conditions Studied
Interventions
- DRUG Docetaxel
- BIOLOGICAL Durvalumab
- OTHER Laboratory Biomarker Analysis
Study Locations (20)
Alaska
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Regional Hospital - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Sutter Auburn Faith Hospital - Auburn
- Kaiser Permanente-Baldwin Park - Baldwin Park
Arizona
- University of Arizona Cancer Center-North Campus - Tucson
- The University of Arizona Medical Center-University Campus - Tucson
- Yuma Cancer Center - Yuma
Arkansas
- Mercy Cancer Center-Hot Springs - Hot Springs
- Fowler Family Center for Cancer Care - Jonesboro
- University of Arkansas for Medical Sciences - Little Rock
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2014-07-31 |
| Est. Completion | 2020-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02766335
The ClinicalTrials.gov registry entry for NCT02766335 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 123-participant average among 3 other Recurrent Squamous Cell Lung Carcinoma trials with a reported enrollment target. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Squamous Cell Lung Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT02766335 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Alaska, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT02766335 about?
NCT02766335 is a clinical study titled "Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers". This phase II trial studies how well durvalumab works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a "non-match" sub-study that includes all screened patients not eligible for a biomarker-driven sub-study. Monoclonal antibodies, su...
What is the current status of trial NCT02766335?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2014-07-31. Estimated completion is 2020-09.
What conditions does trial NCT02766335 study?
This clinical trial studies the following conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7.
What interventions are being tested in trial NCT02766335?
The interventions under investigation include: Docetaxel (DRUG), Durvalumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02766335?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02766335 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Squamous Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lung-MAP S1400K: c-MET Positive
COMPLETED · Phase 2
-
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
COMPLETED · Phase 2
-
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Recurrent Squamous Cell Lung Carcinoma
All registered trials for this condition
Stage IV Squamous Cell Lung Carcinoma AJCC v7
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.